NCT05330637 is a clinical trial of Climate and environment in Sanya in Asthma, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT05330637?

NCT05330637 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT05330637?

Interventions in NCT05330637: Climate and environment in Sanya.

What condition does NCT05330637 study?

NCT05330637 studies Asthma, Allergic Rhinitis, Chronic Obstructive Pulmonary Disease(COPD), Atopic Dermatitis, Eczema, Urticaria, Bronchitis, Bronchiectasis Adult, Emphysema.

Is NCT05330637 still recruiting?

NCT05330637 is currently status unknown. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT05330637

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.

Status unknown Last updated 11 September 2023

What this trial tests

trial testing Climate and environment in Sanya in Asthma in 800 participants. Status unknown.

Timeline

3 March 2022

Primary endpoint
31 December 2023

30 April 2025

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	800
Start date	3 March 2022
Primary completion	31 December 2023
Estimated completion	30 April 2025
Sites	1 location across China

Drugs / interventions tested

Climate and environment in Sanya

Conditions studied

Asthma — all drugs for Asthma →
Allergic Rhinitis — all drugs for Allergic Rhinitis →
Chronic Obstructive Pulmonary Disease(COPD) — all drugs for Chronic Obstructive Pulmonary Disease(COPD) →
Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 3 to 80, any sex, with Asthma or Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the Influence of Climatic and Environmental Factors on Respiratory or Allergic Diseases in Sanya.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of climate and environment on migratory old people with allergic diseases in China: Protocol for a Sanya cohort study.
Hu Q, Shi X, Wang D, Huang Y, et al · · 2023 · cited 2× · PMID 38045199 · DOI 10.1016/j.heliyon.2023.e21949

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05330637 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing